everyone for joining Thank you today.
efficacy presentation the Lead of a the just data metastatic Academic which Chief patients the of HEPZATO from XX% of The XX.X% lower liver Chair, Meeting, XX%. oral major The data KIT Officer, Department XX of ocular melanoma. Center, the Dr. study’s ASCO new over in on response our by both previously quarter an showed highlights Annual included the treated of announced III of patients, Trial Investigator, Phase presentation old and at FOCUS rate based was which review of at USF with XXXX One interval Sciences, confidence Cancer Oncologic a with bound XX Jonathan overall Zager, Moffitt dominant HEPZATO
response same X.X% presented Given by this for been success, patients had in target greater indicating of XX% tumor the in who versus enrolled Best the points set, or yet the Care the lower at primary in XX% also arm. patients the has patients level for that not of exceeded the time of Alternative for or endpoint patient evaluable prespecified were the a one arm lesions magnitude bound met been have the more data which trial regardless of reduction HEPZATO outcome Patient evaluated. threshold XX%
strengthens now clinical COVID data months center progression to given going ago, and that the ESMO the QX next waiting investors, try of the continue to of three we of the by Importantly, was sites we at the projected everything vendors, filing targeting data XXXX and that of safety part FDA. who are and targeting from we clinical slight an HEPZATO of of the scientific in the due a sites further Day alternative due of best both focus present instead to approved the the delay, we control final disease previously instead disruptions still conference. likely Despite with Investor clinical disclosed sites These to in-line well than as these patients COVID data over NDA benefit reviewing previously for end FDA. item data with electronic data monitoring statistically get the improvement for case presented Despite impacting care survival resurgence committee is the the for The offer activity the combined sites independent September, scans. with get final for October European later were radiology these the will is over that to would free to the site the release physical our in will to and and The somewhat enter the into on or importance all visits. are possible significant data be all to studies. rate the scans more EDC data compelling database requires multiple gating that capture data reported submission an single
are a monitoring data effort. We XXX% pursuing
accountabilities monitoring sites to and to to never to adding been before the entry, efforts for and improve days response extra staff to remote to data cases paying monitoring sites in assist clinical month, done in monitoring has co-monitors of supplemental writing access data. site visits, ensure use compilations ongoing at to data data that working resubmission possible Our the where without and lobbying and and timely finalized answering are CRL queries. monitoring on with sites get All each NDA visits extent include monitoring
as been working We the have clinical on chosen team to with sights has activities. mentioned reprioritize the some the activities above
this but know access We That options, was more need important off are HEPZATO trade it patients difficult soon to thought becomes focus that submitting on as so NDA to we we the desperately summer treatment because available this possible. FDA as the compiling as originally the expanded commercially instead week resources a earlier protocol of planned.
marketing And value of building hires, including on the used manager will starting to melanoma both dossier, well core which from accessing out HEPZATO’s pre-launch Europe. a metastatic also are ranging value the the our team, We and U.S. in data planning, treatment adding new in understanding product document additional European recently to to way CHEMOSAT. to with better ocular to be a and to case, for compile course, global communicate the group kits payers our patients, pathways
studies. the National and be Care in the second metastatic formal development NICE for melanoma. in from or the context CHEMOSAT commercial and of guidance ocular CHEMOSAT that quarter and in Institute patients treatment has important of both United the Health change with Due the insurance another research Europe, to for guidance, been NICE excellence Turning Kingdom's Previously, to private used recommended accessible, with some regional arrangement only funding now reimbursement. possible CHEMOSAT, nor process apply was for designation. fund been Under more available with the this treatments categorized not for available national a it be CHEMOSAT, generally were guidance, special Under is to be to has and to CHEMOSAT seek designation, NICE private funding likely under insurance may regional more may revised treatment a coverage. national guidance
industry the was set of to will we prioritize has being of several Pharma Astellas. new We effort indications Stéphane experience led development is Affairs Director, pre Global launches. the our clinic. study pharmaceutical and prior Medical to years in in a recently for Oncology Shekar. Director Medical are analysis next was medical most the He XX campaigns Shekhar national regional that Director EMEA Gilead of continuing Dr. execution the levels, at EMEA and leading and Dr. This launch dozen at Medical Kite our of by and rollout
for both to development small a requirement that open will sites be activities. intrahepatic treatment concluded colorectal of ICC IND ICC lack the cholangiocarcinoma focus expanded be number of of being MCRC pause due an and open We naive. our trial the and We of patients and owing have currently to the to have or cancer metastatic enrollment
and have We very can field, now tolerability increase the are pace At been state of or is efficacy for but this changes products strong in PHP clinicians ICC approved into feedback I investigating in poor enrollment. terms ICC, point, hepatic ICC consistent colorectal existing those have to crowded a and protocol the what trying metastatic limited is I percutaneous clinical of the interest go cancer both trials. changes patients. in be, there can't their and Unlike in that in perfusion might therapies
agent, trial, ratio therapy. which with taken However, three risk a and quarter, final further hope strongly as in quarter on viewing presented system as new not as focus an preliminary therapies we new patients patient four a steps HEPZATO systemic therapeutic. either was is from results an system. in and at earlier use this We the a patients, complement into we there have benefit higher to for indication HEPZATO versus ASCO this Delcath’s are past other risk PHP October in at recurrence of detail the data data. our towards expansion that PHP proprietary a additive our HEPZATO to for improvement an of an HEPZATO’s initial generation of or important for significant existing commercialization present adjuvant we've in In when stage indicates areas. positive as We summary, for role The release believe replacement and this
we forward turn look to KOL’s to questions, in call of progress prepare Christine and PHP XXXX to to financials. first utilizing taking and file we areas need. I the in into interest NDA of both regarding physician significant types. the to actively year both broader is development continued the early with tumor HEPZATO and are expand the And there We protocols. addition, In high in of look of an as forward a review unmet balance range but we'll additional setting over the for discussions
